On September 12th, Labi Baby announced in a statement that, based on its strategic plan for investments in medical aesthetics, the company intends to acquire a 13% equity stake in Guangdong Hanfei Hospital Investment Co., Ltd. held by Shanghai Jian’ermei for a total of 59.5059 million yuan ($8.17 million). After the completion of this transaction, the company will hold a 49% stake (without forming control) in Guangdong Hanfei.
According to the announcement, the target company has been deeply involved in the medical aesthetics industry for over a decade. As of now, it holds controlling or participating interests in five medical aesthetics institutions located in Yuexiu District, Guangzhou; Tianhe District, Guangzhou; Zhuhai City; Zhongshan City; and Huizhou City. It has approximately 700 employees and a medical aesthetics space of around 20,000 square meters, providing various medical aesthetics and health management services to consumers in the medical aesthetics field.
Labi Baby stated that this investment is based on its strategic plan for investments in medical aesthetics, as well as its long-term optimism about the medical aesthetics industry, the company’s qualifications, technology, management team, and business development in Guangdong Hanfei.
According to public reports, Labi Baby was established in 1996 and went public on the Shenzhen Stock Exchange in 2015 as the “first stock in the mother and baby industry.” It operates in the mother and baby consumer goods industry and owns brands such as Labi Baby, Xiayidai, and Baby Labi. In April 2021, facing a decline in its main business, Labi Baby chose to diversify into the medical aesthetics industry and acquired a 36% equity stake in Guangdong Hanfei, which temporarily boosted its stock price.
